MedTrace Logo

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

NCT06284850 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-02-29

No results posted yet for this study

Summary

The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and reno- protective effect of SGLT-2 inhibitors.

Conditions

  • Hematocrit Change
  • Cardiovascular Prevention
  • Empagliflozin
  • SGLT2-Inhibitors
  • Tissue Oxygenation

Interventions

DRUG

Empagliflozin10Mg Tab

TB JARDIANCE 10MG

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • KONSTANTINOS KITSIOS, MD,MSc,PhD · Aristotle University of Thessaloniki 3d Department of Internal Medicine, Papageorgiou General Hospital, Thessaloniki, Greece

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06284850 on ClinicalTrials.gov